Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alto Neuroscience, Inc.(ANRO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANRO
09/25/2026: ANRO (2-star) is currently NOT-A-BUY. Pass it for now.
Alto Neuroscience is a clinical-stage biotechnology company that utilizes an AI-driven, biomarker-based platform to develop precision medicines for psychiatric disorders. Its primary strength lies in its potential to improve success rates in drug development by identifying patient subgroups most likely to respond to therapy. The main investment opportunity is the potential for its lead candidates, such as ALTO-100, to disrupt the psychiatric market. However, the company faces significant risks including clinical trial uncertainty, high cash burn, and intense competition from established pharmaceutical firms. This stock is best suited for growth-oriented investors who can tolerate significant volatility associated with binary clinical data outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical breakthroughs but lacks current commercial revenue. |
| Momentum investor | Weak fit | Momentum is highly dependent on binary clinical trial news events which create significant short-term price volatility. |
| Value investor | Weak fit | Valuation is speculative and based on long-term drug development potential rather than current cash flows or assets. |
| Dividend investor | Weak fit | The company is a loss-making biotech reinvesting all cash, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | The high failure rate of clinical-stage biotech makes this stock inappropriate for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause massive swings in stock price. |
| Valuation risk | High | Valuations are based on speculative long-term success rather than current earnings. |
| Competition risk (Psychiatric drug developers) | Medium / high | Large incumbents with deep pockets compete for the same market share. |
| Business quality | Medium | The company is in an early, pre-commercial phase of development. |
| Dividend income | Low / none | No dividend payments exist or are expected in the near term. |
| Execution risk | High | The complexity of clinical development and regulatory approval is a major hurdle. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 5.81% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio - | 1Y Target Price 38.38 |
Price to earnings Ratio - | 1Y Target Price 38.38 | ||
Volume (30-day avg) 545.4K shares | Beta 1.16 | 52 Weeks Range 3.91 - 37.48 | Updated Date 09/25/2026 |
52 Weeks Range 3.91 - 37.48 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.29 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Development | Currently, the company does not generate commercial revenue and funds operations through capital raises. | The company is a clinical-stage research entity, not a commercial product seller, so revenue is not currently a metric. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 858.72M | Price to Sales(TTM) - |
Enterprise Value 858.72M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 39.24M | Shares Floating 29.65M |
Shares Outstanding 39.24M | Shares Floating 29.65M | ||
Percent Insiders 4.07 | Percent Institutions 87.05 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquarters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, CEO & Chairman of the Board Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | Website https://www.altoneuroscience.com |
Full time employees 68 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.